NASDAQ:FOLD - Amicus Therapeutics Stock Price, Price Target & More

$14.21 -0.43 (-2.94 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$14.21
Today's Range$14.16 - $14.82
52-Week Range$6.41 - $17.40
Volume2.16 million shs
Average Volume3.09 million shs
Market Capitalization$2.78 billion
P/E Ratio-4.87
Dividend YieldN/A
Beta1.46

About Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics logoAmicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:FOLD
CUSIP03152W10
Phone609-662-2000

Debt

Debt-to-Equity Ratio0.47%
Current Ratio5.60%
Quick Ratio5.53%

Price-To-Earnings

Trailing P/E Ratio-4.87
Forward P/E Ratio-10.45
P/E GrowthN/A

Sales & Book Value

Annual Sales$36.93 million
Price / Sales72.33
Cash FlowN/A
Price / CashN/A
Book Value$2.12 per share
Price / Book6.70

Profitability

EPS (Most Recent Fiscal Year)($2.92)
Net Income$-284,000,000.00
Net Margins-769.03%
Return on Equity-71.06%
Return on Assets-29.39%

Miscellaneous

Employees325
Outstanding Shares187,970,000

How to Become a New Pot Stock Millionaire

Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics (NASDAQ:FOLD) released its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.11. The biopharmaceutical company earned $14.73 million during the quarter, compared to analyst estimates of $14.50 million. Amicus Therapeutics had a negative net margin of 769.03% and a negative return on equity of 71.06%. View Amicus Therapeutics' Earnings History.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Amicus Therapeutics.

What price target have analysts set for FOLD?

7 Wall Street analysts have issued twelve-month price objectives for Amicus Therapeutics' shares. Their forecasts range from $15.00 to $24.00. On average, they expect Amicus Therapeutics' stock price to reach $19.50 in the next year. View Analyst Ratings for Amicus Therapeutics.

Are investors shorting Amicus Therapeutics?

Amicus Therapeutics saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 27,987,959 shares, an increase of 3.8% from the March 15th total of 29,104,959 shares. Based on an average daily volume of 2,143,412 shares, the days-to-cover ratio is presently 13.1 days. Approximately 15.4% of the company's shares are short sold.

Who are some of Amicus Therapeutics' key competitors?

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the folowing people:
  • Mr. John F. Crowley, Chairman and Chief Exec. Officer (Age 51)
  • Mr. Bradley L. Campbell, Pres and Chief Operating Officer (Age 42)
  • Mr. William D. Baird III, Chief Financial Officer (Age 46)
  • Dr. Hung Do Ph.D., Chief Science Officer (Age 50)
  • Dr. Jay A. Barth M.D., Chief Medical Officer (Age 54)

Has Amicus Therapeutics been receiving favorable news coverage?

News headlines about FOLD stock have trended somewhat positive on Saturday, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amicus Therapeutics earned a media sentiment score of 0.19 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.63 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include PRUDENTIAL FINANCIAL INC (6.20%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $14.21.

How big of a company is Amicus Therapeutics?

Amicus Therapeutics has a market capitalization of $2.78 billion and generates $36.93 million in revenue each year. The biopharmaceutical company earns $-284,000,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Amicus Therapeutics employs 325 workers across the globe.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]


MarketBeat Community Rating for Amicus Therapeutics (FOLD)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  310 (Vote Outperform)
Underperform Votes:  179 (Vote Underperform)
Total Votes:  489
MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe FOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amicus Therapeutics (NASDAQ:FOLD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Amicus Therapeutics in the last 12 months. Their average twelve-month price target is $19.50, suggesting that the stock has a possible upside of 37.23%. The high price target for FOLD is $24.00 and the low price target for FOLD is $15.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.862.86
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.50$19.50$18.6429$18.0714
Price Target Upside: 37.23% upside17.75% upside20.20% upside13.09% upside

Amicus Therapeutics (NASDAQ:FOLD) Consensus Price Target History

Price Target History for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018Leerink SwannBoost Price TargetOutperform -> Outperform$20.00 -> $24.00HighView Rating Details
2/7/2018Robert W. BairdSet Price TargetBuy$20.00HighView Rating Details
1/10/2018CowenReiterated RatingBuy$22.00MediumView Rating Details
10/6/2017Goldman SachsReiterated RatingNeutral -> Neutral$17.00N/AView Rating Details
10/5/2017Chardan CapitalReiterated RatingBuy$16.50 -> $18.50N/AView Rating Details
10/4/2017JPMorgan ChaseReiterated RatingOverweightN/AView Rating Details
10/4/2017Bank of AmericaBoost Price TargetBuy$15.00 -> $20.00HighView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Amicus Therapeutics (NASDAQ:FOLD) Earnings History and Estimates Chart

Earnings by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD) Earnings Estimates

2018 EPS Consensus Estimate: ($1.47)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.37)($0.37)($0.37)
Q2 20181($0.37)($0.37)($0.37)
Q3 20181($0.37)($0.37)($0.37)
Q4 20181($0.36)($0.36)($0.36)

Amicus Therapeutics (NASDAQ FOLD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.33)N/AView Earnings Details
2/28/2018Q4 2017($0.30)($0.41)$14.50 million$14.73 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.31)($0.41)$9.02 million$10.90 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.37)($0.34)$6.96 million$7.16 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.37)($0.39)$4.16 million$4.20 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.33)($0.32)$3.16 million$2.83 millionViewListenView Earnings Details
11/7/2016Q3($0.31)($0.33)$1.71 million$2.10 millionViewListenView Earnings Details
8/9/2016Q2($0.33)($0.40)$0.17 millionViewN/AView Earnings Details
5/3/2016Q1($0.34)($0.35)ViewListenView Earnings Details
2/26/2016Q4 2015($0.31)($0.35)ViewN/AView Earnings Details
11/3/2015Q3($0.25)($0.32)ViewN/AView Earnings Details
8/5/2015Q215($0.24)($0.26)ViewN/AView Earnings Details
5/5/2015Q115($0.14)($0.25)$0.50 millionViewN/AView Earnings Details
3/3/2015Q414($0.18)($0.24)$0.48 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.21)($0.22)$1.00 million$0.29 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.24)($0.23)$0.48 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.23)($0.25)$0.20 million$0.46 millionViewN/AView Earnings Details
3/3/2014Q4 13($0.32)($0.22)$0.32 millionViewN/AView Earnings Details
11/11/2013Q3($0.3220)($0.29)$0.04 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.35)($0.31)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.30)($0.34)ViewN/AView Earnings Details
3/12/2013Q4 2012($0.36)($0.23)ViewN/AView Earnings Details
11/5/2012Q312($0.24)($0.31)$8.82 million$5.80 millionViewN/AView Earnings Details
8/7/2012Q2 2012($0.23)($0.20)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.34)($0.28)ViewN/AView Earnings Details
2/13/2012Q4 2011($0.37)$0.23ViewN/AView Earnings Details
11/1/2011Q3 2011($0.33)($0.38)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.32)($0.31)ViewN/AView Earnings Details
5/4/2011Q1 2011($0.35)($0.29)ViewN/AView Earnings Details
2/14/2011Q4 2010($0.15)($0.45)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.49)($0.48)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.53)($0.41)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.57)($0.54)ViewN/AView Earnings Details
2/16/2010Q4 2009($0.59)$1.45ViewN/AView Earnings Details
10/29/2009Q3 2009($0.71)($0.59)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.63)($0.60)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.60)($0.55)ViewN/AView Earnings Details
2/5/2009Q4 2008($0.54)($0.63)ViewN/AView Earnings Details
11/3/2008Q3 2008($0.44)($0.36)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.45)($0.41)ViewN/AView Earnings Details
5/13/2008Q1 2008($0.39)($0.35)ViewN/AView Earnings Details
1/29/2008Q4 2007($0.35)($0.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Amicus Therapeutics (NASDAQ:FOLD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Amicus Therapeutics (NASDAQ FOLD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.40%
Insider Trading History for Amicus Therapeutics (NASDAQ:FOLD)
Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ FOLD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/17/2018Hung DoInsiderSell50,000$15.00$750,000.00446,771View SEC Filing  
4/16/2018Michael RaabDirectorSell5,000$14.41$72,050.0010,814View SEC Filing  
4/12/2018Jay BarthInsiderSell5,000$14.72$73,600.0090,409View SEC Filing  
4/2/2018Kurt J AndrewsSVPSell5,000$14.27$71,350.0045,469View SEC Filing  
4/2/2018William D Baird IIICFOSell10,000$14.26$142,600.00127,662View SEC Filing  
3/12/2018Jay BarthInsiderSell5,000$15.05$75,250.0090,409View SEC Filing  
3/9/2018Daphne QuimiSVPSell8,750$15.00$131,250.0073,082View SEC Filing  
3/5/2018Perceptive Advisors LlcMajor ShareholderBuy335,827$13.56$4,553,814.12View SEC Filing  
3/1/2018Daphne QuimiSVPSell8,149$14.06$114,574.9472,481View SEC Filing  
3/1/2018Life Sciences Maste PerceptiveMajor ShareholderBuy100,000$13.69$1,369,000.00View SEC Filing  
1/23/2018Jay BarthInsiderSell20,000$16.80$336,000.00105,409View SEC Filing  
1/22/2018Bradley L CampbellCOOSell32,500$15.92$517,400.00186,600View SEC Filing  
1/2/2018Daphne QuimiSVPSell8,000$14.72$117,760.0062,676View SEC Filing  
1/2/2018Donald J Hayden JrDirectorSell20,000$15.00$300,000.0025,814View SEC Filing  
1/2/2018Jay BarthInsiderSell5,000$14.71$73,550.0069,184View SEC Filing  
1/2/2018William D Baird IIICFOSell10,000$14.72$147,200.00105,121View SEC Filing  
12/29/2017John F CrowleyCEOSell18,970$14.75$279,807.50View SEC Filing  
12/29/2017John F CrowleyCEOSell5,920$14.75$87,320.00341,051View SEC Filing  
12/21/2017John F CrowleyCEOSell65,581$13.51$885,999.31393,076View SEC Filing  
12/11/2017John F CrowleyCEOSell12,206$13.52$165,025.12340,207View SEC Filing  
12/4/2017John F CrowleyCEOSell47,213$13.61$642,568.93375,214View SEC Filing  
12/1/2017Jay BarthInsiderSell5,000$13.59$67,950.0069,184View SEC Filing  
10/18/2017John F CrowleyCEOSell71,735$14.75$1,058,091.25380,723View SEC Filing  
10/16/2017John F CrowleyCEOSell449,295$14.33$6,438,397.35380,723View SEC Filing  
10/12/2017Daphne QuimiSVPSell7,000$14.25$99,750.00View SEC Filing  
10/12/2017Hung DoInsiderSell50,194$14.25$715,264.50View SEC Filing  
10/12/2017Michael RaabDirectorSell10,000$14.25$142,500.00View SEC Filing  
10/12/2017William D Baird IIICFOSell40,000$14.25$570,000.00View SEC Filing  
9/26/2017John F CrowleyCEOBuy1,395$14.36$20,032.20328,001View SEC Filing  
7/13/2017Life Sciences Maste PerceptiveMajor ShareholderBuy1,500,000$12.25$18,375,000.00View SEC Filing  
6/19/2017Jay BarthInsiderSell30,000$10.00$300,000.0064,184View SEC Filing  
5/19/2017Hung DoInsiderSell29,914$8.00$239,312.00474,438View SEC Filing  
3/2/2017Bradley L CampbellCOOSell49,050$8.00$392,400.00127,475View SEC Filing  
1/13/2017Hung DoInsiderSell25,000$6.00$150,000.00559,266View SEC Filing  
12/30/2016Perceptive Advisors LlcMajor ShareholderBuy94,750$4.96$469,960.00View SEC Filing  
12/29/2016Perceptive Advisors LlcMajor ShareholderBuy142,125$4.87$692,148.75View SEC Filing  
12/23/2016Perceptive Advisors LlcMajor ShareholderBuy85,275$4.81$410,172.75View SEC Filing  
12/22/2016Perceptive Advisors LlcMajor ShareholderBuy189,500$4.51$854,645.00View SEC Filing  
11/9/2016Daphne QuimiSVPSell8,546$8.00$68,368.0024,189View SEC Filing  
11/1/2016Hung DoInsiderSell25,000$7.00$175,000.00533,453View SEC Filing  
10/3/2016Hung DoInsiderSell25,000$7.25$181,250.00558,453View SEC Filing  
9/20/2016William D Baird IIICFOSell20,500$8.00$164,000.0056,450View SEC Filing  
9/6/2016Hung DoInsiderSell25,000$7.00$175,000.00583,453View SEC Filing  
8/25/2016Perceptive Advisors LlcInsiderSell1,100,000$6.81$7,491,000.00View SEC Filing  
8/4/2016Jay BarthInsiderSell10,458$7.00$73,206.0015,000View SEC Filing  
7/27/2016Jay BarthInsiderSell20,916$7.00$146,412.0025,458View SEC Filing  
6/2/2016Ellen RosenbergGeneral CounselBuy15,000$7.67$115,050.00View SEC Filing  
11/10/2015Margaret G McglynnDirectorBuy10,000$10.27$102,700.0010,000View SEC Filing  
10/7/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.27$313,500.00View SEC Filing  
10/6/2015Perceptive Advisors LlcMajor ShareholderBuy750,000$6.71$5,032,500.00View SEC Filing  
10/1/2015Kenneth PeistVPSell10,000$13.14$131,400.003,187View SEC Filing  
9/21/2015Bradley L. CampbellCOOSell13,001$16.78$218,156.78156,575View SEC Filing  
9/21/2015William D. Baird IIICFOSell15,236$16.78$255,660.0856,575View SEC Filing  
9/15/2015Hung DoInsiderSell25,000$17.75$443,750.00720,953View SEC Filing  
9/14/2015Daphne QuimiVPSell2,500$18.08$45,200.005,688View SEC Filing  
7/16/2015John F CrowleyCEOSell16,025$16.00$256,400.00View SEC Filing  
7/14/2015John F CrowleyCEOSell142,250$15.03$2,138,017.50View SEC Filing  
7/13/2015Glenn SblendorioDirectorSell10,000$15.00$150,000.00View SEC Filing  
7/13/2015John F CrowleyCEOSell7,750$15.01$116,327.50View SEC Filing  
7/13/2015Ken ValenzanoSVPSell15,000$15.00$225,000.00View SEC Filing  
7/8/2015Dipal DoshiSVPSell6,250$13.87$86,687.50View SEC Filing  
7/1/2015Jayne GershkowitzSVPSell10,649$13.97$148,766.53View SEC Filing  
7/1/2015Kenneth PeistVPSell10,000$13.98$139,800.00View SEC Filing  
6/23/2015Donald J Hayden JrDirectorSell55,000$14.01$770,550.00View SEC Filing  
6/22/2015Jeff CastelliSVPSell18,981$13.94$264,595.14View SEC Filing  
6/19/2015Bradley L CampbellCOOSell13,000$13.26$172,380.00View SEC Filing  
6/19/2015Enrique DiloneSVPSell14,045$13.26$186,236.70View SEC Filing  
6/19/2015William D Baird IIICFOSell15,235$13.26$202,016.10View SEC Filing  
6/15/2015Jeff CastelliSVPSell7,377$14.17$104,532.09View SEC Filing  
6/15/2015Julie YuVPSell8,195$14.17$116,123.15View SEC Filing  
6/8/2015Jeff CastelliSVPSell17,312$12.87$222,805.44View SEC Filing  
6/8/2015John F CrowleyCEOSell55,000$13.01$715,550.00View SEC Filing  
5/11/2015Jeff CastelliSVPSell10,000$10.84$108,400.00View SEC Filing  
5/11/2015Kenneth PeistVPSell12,500$10.84$135,500.00View SEC Filing  
5/11/2015William D Baird IIICFOSell24,800$10.84$268,832.00View SEC Filing  
4/15/2015Glenn SblendorioDirectorSell20,000$12.50$250,000.00View SEC Filing  
4/15/2015Ken ValenzanoVPSell5,000$12.50$62,500.00View SEC Filing  
4/10/2015John F CrowleyCEOSell11,678$12.00$140,136.00View SEC Filing  
4/1/2015Jeff CastelliVPSell9,489$10.69$101,437.41View SEC Filing  
1/5/2015Jeff CastelliVPSell4,667$9.00$42,003.00View SEC Filing  
12/4/2014John F CrowleyCEOSell89,000$8.36$744,040.00View SEC Filing  
11/25/2014Bradley L CampbellCOOSell7,250$8.00$58,000.00View SEC Filing  
11/25/2014Jeff CastelliVPSell8,103$8.00$64,824.00View SEC Filing  
11/25/2014William D Baird IIICFOSell10,000$8.00$80,000.00View SEC Filing  
11/19/2014Perceptive Advisors LlcMajor ShareholderBuy2,100,000$6.50$13,650,000.00View SEC Filing  
10/27/2014Plc GlaxosmithklineMajor ShareholderSell11,315,825$5.29$59,860,714.25View SEC Filing  
10/3/2014Jeff CastelliVPSell8,552$7.00$59,864.00View SEC Filing  
10/3/2014William D Baird IIICFOSell10,000$7.00$70,000.00View SEC Filing  
10/2/2014Julie YuVPSell4,759$5.99$28,506.41View SEC Filing  
9/29/2014Daphne QuimiVPSell10,738$6.10$65,501.80View SEC Filing  
9/29/2014William D Baird IIICFOSell25,311$6.09$154,143.99View SEC Filing  
8/27/2014Glenn SblendorioDirectorSell10,000$6.50$65,000.00View SEC Filing  
8/27/2014Jayne GershkowitzVPSell5,000$7.00$35,000.00View SEC Filing  
8/25/2014Bradley L CampbellCOOSell7,000$6.00$42,000.00View SEC Filing  
8/25/2014Jayne GershkowitzVPSell5,000$6.00$30,000.00View SEC Filing  
8/20/2014Bradley L CampbellCOOSell18,750$5.40$101,250.00View SEC Filing  
8/20/2014Enrique DiloneVPSell12,810$5.40$69,174.00View SEC Filing  
6/30/2014Perceptive Advisors LlcMajor ShareholderBuy4,000,000$3.50$14,000,000.00View SEC Filing  
11/20/2013Plc Glaxosmithklinemajor shareholderBuy1,500,000$2.00$3,000,000.00View SEC Filing  
3/15/2013Sol J BarerDirectorBuy25,000$3.40$85,000.00View SEC Filing  
11/13/2012Joan WinterbottomSVPBuy1,665$4.54$7,559.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amicus Therapeutics (NASDAQ FOLD) News Headlines

Source:
DateHeadline
Technical Perspectives on Biotech Stocks -- Alnylam Pharma, Amgen, Amicus Therapeutics, and Ampio PharmaTechnical Perspectives on Biotech Stocks -- Alnylam Pharma, Amgen, Amicus Therapeutics, and Ampio Pharma
www.prnewswire.com - April 20 at 8:01 AM
Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock OptionsImplied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options
www.zacks.com - April 20 at 8:01 AM
Amicus Therapeutics (FOLD) Insider Hung Do Sells 50,000 SharesAmicus Therapeutics (FOLD) Insider Hung Do Sells 50,000 Shares
www.americanbankingnews.com - April 19 at 7:34 PM
Zacks Investment Research Downgrades Amicus Therapeutics (FOLD) to SellZacks Investment Research Downgrades Amicus Therapeutics (FOLD) to Sell
www.americanbankingnews.com - April 19 at 12:28 AM
Amicus Therapeutics (FOLD) Director Sells $72,050.00 in StockAmicus Therapeutics (FOLD) Director Sells $72,050.00 in Stock
www.americanbankingnews.com - April 18 at 7:49 PM
Jay Barth Sells 5,000 Shares of Amicus Therapeutics (FOLD) StockJay Barth Sells 5,000 Shares of Amicus Therapeutics (FOLD) Stock
www.americanbankingnews.com - April 16 at 7:14 PM
Portfolio Review: Continued Market Outperformance In Q1 2018Portfolio Review: Continued Market Outperformance In Q1 2018
seekingalpha.com - April 15 at 8:43 AM
Amicus Therapeutics (FOLD) Receives Consensus Recommendation of "Buy" from AnalystsAmicus Therapeutics (FOLD) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 15 at 3:25 AM
$16.78 Million in Sales Expected for Amicus Therapeutics (FOLD) This Quarter$16.78 Million in Sales Expected for Amicus Therapeutics (FOLD) This Quarter
www.americanbankingnews.com - April 14 at 4:39 AM
Amicus Therapeutics (FOLD) Rating Lowered to Buy at BidaskClubAmicus Therapeutics (FOLD) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 14 at 12:49 AM
Amicus Therapeutics (FOLD) Lifted to "Buy" at BidaskClubAmicus Therapeutics (FOLD) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - April 13 at 11:05 AM
Zacks: Analysts Expect Amicus Therapeutics (FOLD) Will Post Earnings of -$0.36 Per ShareZacks: Analysts Expect Amicus Therapeutics (FOLD) Will Post Earnings of -$0.36 Per Share
www.americanbankingnews.com - April 12 at 5:23 AM
Amicus Therapeutics Sees Unusually High Options Volume (FOLD)Amicus Therapeutics Sees Unusually High Options Volume (FOLD)
www.americanbankingnews.com - April 11 at 7:06 AM
Amicus Therapeutics (FOLD) PT Raised to $17.50Amicus Therapeutics (FOLD) PT Raised to $17.50
www.americanbankingnews.com - April 10 at 11:38 PM
Amicus Therapeutics (FOLD) Upgraded at Zacks Investment ResearchAmicus Therapeutics (FOLD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 7 at 3:52 PM
Amicus Therapeutics (FOLD) SVP Sells $71,350.00 in StockAmicus Therapeutics (FOLD) SVP Sells $71,350.00 in Stock
www.americanbankingnews.com - April 4 at 11:18 PM
William D. Baird III Sells 10,000 Shares of Amicus Therapeutics (FOLD) StockWilliam D. Baird III Sells 10,000 Shares of Amicus Therapeutics (FOLD) Stock
www.americanbankingnews.com - April 4 at 11:17 PM
Amicus Therapeutics (FOLD) Upgraded to "Buy" at ValuEngineAmicus Therapeutics (FOLD) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - April 3 at 3:35 PM
Amicus Therapeutics (FOLD) Rating Lowered to Hold at BidaskClubAmicus Therapeutics (FOLD) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 30 at 2:19 PM
3 Biotech Stocks a Pro Is Buying Now3 Biotech Stocks a Pro Is Buying Now
www.barrons.com - March 30 at 8:16 AM
[$$] 3 Biotech Stocks a Pro Is Buying Now[$$] 3 Biotech Stocks a Pro Is Buying Now
finance.yahoo.com - March 30 at 8:16 AM
Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in JapanAmicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan
finance.yahoo.com - March 30 at 8:16 AM
Amicus Therapeutics, Inc. (FOLD) Short Interest UpdateAmicus Therapeutics, Inc. (FOLD) Short Interest Update
www.americanbankingnews.com - March 29 at 3:10 AM
Amicus Therapeutics (FOLD) Raised to "Hold" at Zacks Investment ResearchAmicus Therapeutics (FOLD) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 27 at 11:28 PM
Amicus Therapeutics (FOLD) Upgraded to "Hold" at ValuEngineAmicus Therapeutics (FOLD) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - March 25 at 5:54 PM
Zacks Investment Research Upgrades Amicus Therapeutics (FOLD) to "Hold"Zacks Investment Research Upgrades Amicus Therapeutics (FOLD) to "Hold"
www.americanbankingnews.com - March 24 at 12:28 AM
Amicus Therapeutics Announces Approval of Galafold® (Migalastat ... - GlobeNewswire (press release)Amicus Therapeutics Announces Approval of Galafold® (Migalastat ... - GlobeNewswire (press release)
globenewswire.com - March 23 at 8:00 AM
Amicus Therapeutics Galafold OKd in Japan for Fabry diseaseAmicus Therapeutics' Galafold OK'd in Japan for Fabry disease
seekingalpha.com - March 23 at 7:13 AM
Amicus Therapeutics, Inc. (FOLD) Receives Consensus Rating of "Buy" from AnalystsAmicus Therapeutics, Inc. (FOLD) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 21 at 3:28 AM
Amicus Therapeutics (FOLD) Presents At Barclays Global Healthcare Conference 2018 - SlideshowAmicus Therapeutics (FOLD) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
seekingalpha.com - March 16 at 6:47 PM
After Hours Most Active for Mar 14, 2018 : QQQ, FOLD, F, MSFT, QEP, GM, USMC, BEN, CMCSA, BSX, CNP, EXEL - NasdaqAfter Hours Most Active for Mar 14, 2018 : QQQ, FOLD, F, MSFT, QEP, GM, USMC, BEN, CMCSA, BSX, CNP, EXEL - Nasdaq
www.nasdaq.com - March 14 at 5:42 PM
Jay Barth Sells 5,000 Shares of Amicus Therapeutics, Inc. (FOLD) StockJay Barth Sells 5,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock
www.americanbankingnews.com - March 13 at 8:32 PM
Amicus Therapeutics, Inc. (FOLD) SVP Sells $131,250.00 in StockAmicus Therapeutics, Inc. (FOLD) SVP Sells $131,250.00 in Stock
www.americanbankingnews.com - March 12 at 7:57 PM
$16.78 Million in Sales Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter$16.78 Million in Sales Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter
www.americanbankingnews.com - March 11 at 9:35 AM
 Brokerages Anticipate Amicus Therapeutics, Inc. (FOLD) Will Post Earnings of -$0.36 Per Share Brokerages Anticipate Amicus Therapeutics, Inc. (FOLD) Will Post Earnings of -$0.36 Per Share
www.americanbankingnews.com - March 9 at 1:10 AM
Amicus Therapeutics, Inc. (FOLD) Major Shareholder Perceptive Advisors Llc Buys 335,827 SharesAmicus Therapeutics, Inc. (FOLD) Major Shareholder Perceptive Advisors Llc Buys 335,827 Shares
www.americanbankingnews.com - March 7 at 6:16 PM
Amicus Therapeutics (FOLD) Lifted to Hold at Zacks Investment ResearchAmicus Therapeutics (FOLD) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - March 6 at 10:52 PM
Amicus Therapeutics, Inc. (FOLD) SVP Daphne Quimi Sells 8,149 SharesAmicus Therapeutics, Inc. (FOLD) SVP Daphne Quimi Sells 8,149 Shares
www.americanbankingnews.com - March 5 at 7:18 PM
Life Sciences Maste Perceptive Acquires 100,000 Shares of Amicus Therapeutics, Inc. (FOLD) StockLife Sciences Maste Perceptive Acquires 100,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock
www.americanbankingnews.com - March 5 at 6:22 PM
Amicus Therapeutics, Inc. (FOLD) Stake Boosted by Swiss National BankAmicus Therapeutics, Inc. (FOLD) Stake Boosted by Swiss National Bank
www.americanbankingnews.com - March 5 at 4:04 PM
Sectoral Asset Management Inc Acquires 437,899 Shares of Amicus Therapeutics, Inc. (FOLD)Sectoral Asset Management Inc Acquires 437,899 Shares of Amicus Therapeutics, Inc. (FOLD)
www.americanbankingnews.com - March 5 at 3:33 PM
Leerink Swann Weighs in on Amicus Therapeutics, Inc.s Q1 2018 Earnings (FOLD)Leerink Swann Weighs in on Amicus Therapeutics, Inc.'s Q1 2018 Earnings (FOLD)
www.americanbankingnews.com - March 5 at 2:22 AM
State of Wisconsin Investment Board Raises Position in Amicus Therapeutics, Inc. (FOLD)State of Wisconsin Investment Board Raises Position in Amicus Therapeutics, Inc. (FOLD)
www.americanbankingnews.com - March 4 at 9:32 AM
Amicus Therapeutics, Inc. (FOLD) Shares Bought by Schwab Charles Investment Management Inc.Amicus Therapeutics, Inc. (FOLD) Shares Bought by Schwab Charles Investment Management Inc.
www.americanbankingnews.com - March 3 at 5:56 AM
Head-To-Head Survey: Amicus Therapeutics (FOLD) and Aquinox Pharmaceuticals (AQXP)Head-To-Head Survey: Amicus Therapeutics (FOLD) and Aquinox Pharmaceuticals (AQXP)
www.americanbankingnews.com - March 3 at 1:12 AM
Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates - GlobeNewswire (press release)Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates - GlobeNewswire (press release)
globenewswire.com - March 2 at 8:24 AM
Amicus Therapeutics (FOLD) Posts  Earnings Results, Misses Estimates By $0.11 EPSAmicus Therapeutics (FOLD) Posts Earnings Results, Misses Estimates By $0.11 EPS
www.americanbankingnews.com - March 1 at 11:18 AM
270,900 Shares in Amicus Therapeutics, Inc. (FOLD) Purchased by Spark Investment Management LLC270,900 Shares in Amicus Therapeutics, Inc. (FOLD) Purchased by Spark Investment Management LLC
www.americanbankingnews.com - February 28 at 4:56 PM
1,859,320 Shares in Amicus Therapeutics, Inc. (FOLD) Acquired by Carillon Tower Advisers Inc.1,859,320 Shares in Amicus Therapeutics, Inc. (FOLD) Acquired by Carillon Tower Advisers Inc.
www.americanbankingnews.com - February 28 at 5:32 AM
Amicus Therapeutics, Inc. (FOLD) Shares Bought by American Century Companies Inc.Amicus Therapeutics, Inc. (FOLD) Shares Bought by American Century Companies Inc.
www.americanbankingnews.com - February 28 at 4:18 AM

SEC Filings

Amicus Therapeutics (NASDAQ:FOLD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amicus Therapeutics (NASDAQ:FOLD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amicus Therapeutics (NASDAQ FOLD) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.